



# 2005 annual report

OF THE TREATMENT ACTION GROUP

## Dear Friends of TAG:

I'm proud to share with you TAG's 2005 Annual Report. This was a challenging yet rewarding year of growth for the Treatment Action Group. As you will see, TAG continues to do groundbreaking work as an AIDS research watchdog and as a catalyst for innovative advocacy and research in the United States and around the world.

TAG is broadening the scope of our work with multi-year targeted grants from the Bill & Melinda Gates Foundation (for TB/HIV) and from the Michael Palm Foundation (for basic science, vaccines, and prevention advocacy, beginning in 2006). With some general support from other foundations and corporations, the core of TAG's funding comes from our committed and dedicated base of individual donors. This supports our vital work in:

- antiretroviral drug development advocacy and oversight;
- hepatitis C virus (HCV) coinfection;
- federal affairs, including AIDS research and treatment funding;
- advocacy to defend and extend AIDS research;
- community education; and
- mobilization of people living with HIV/AIDS in the U.S. and around the world.

I believe our supporters share TAG's vision for a world in which everyone with HIV receives the treatment and information necessary to live a long and healthy life, and in which, one day, a vaccine for HIV and a cure for AIDS are discovered and made accessible worldwide.

Unfortunately, as you know, that day is still far off. In this long-term struggle, we need your long-term support. Thank you for your dedication and encouragement for TAG's mission and the work ahead.

Sincerely,  
Barbara Hughes  
Board President



RIAA Presenter **Kathleen Turner**, TAG Board President **Barbara Hughes**, and RIAA Recipient **John Waters**

## Treatment Action Group's 2005 Research in Action Awards Honor State Senator Thomas Duane, AIDS Researcher Dr. Bruce R. Schackman, and Director John Waters

TAG's 2005 Research in Action Awards (RIAA), held at Artists Space in New York City on December 11, 2005, featured a star-studded cast including comedienne **Jackie Hoffman**, photographer **Richard Renaldi**, a **STREB** dance performance, U.S. Senator **Chuck Schumer**, New York State Senator **Tom Duane**, Board President **Barbara Hughes**, ex-TAG board member and Cornell AIDS researcher **Bruce R. Schackman, Ph.D.**, actress **Kathleen Turner**, and renowned film director and artist **John Waters**.

## 2005 at a glance

**January.** Rob Camp, TAG's Antiretroviral Project Director, meets with Tibotec to propose innovative dual-experimental treatment studies for their new antiretrovirals TMC-114 (darunavir, a protease inhibitor) and TMC-125 (an NNRTI). Mark Harrington, TAG's Executive Director, gives a plenary on 15 years of activist involvement in clinical trial design at a NIH conference on **Moving from Observational Studies to Clinical Trials**, and meets with the Office of AIDS Research (OAR) to discuss the upcoming \$500 million clinical trials recompetition. TAG provides guidance to the **Open Society Institute** (OSI) selection of 15 international community groups to receive grants for TB/HIV advocacy.

**February.** NYC Health Commissioner Tom Frieden causes a worldwide stir with a press conference regarding the alleged New York super-drug resistant HIV case, which upon further examination proves to be overstated. TAG's Basic Science, Vaccines, and Prevention Project Director, Richard Jefferys, writes a clarifying critique to *The Lancet*. Tracy Swan, TAG's HIV/HCV Coinfection Project Director, attends the First European HIV/HCV consensus conference and European Community Advisory Board (ECAB) meeting with Schering-Plough, where she confronts Schering on the need to study new drugs in people with HIV/HCV coinfection.

**March.** TAG hires Javid Syed, MPH, as its first TB/HIV Project Director. Throughout his career, Javid has linked community organizing, service provision, and research to inform advocacy around health and social justice issues. He quickly takes control of TAG's project to combat TB/HIV coinfection through a combination of community-based advocacy, education, and mobilization efforts involving AIDS advocates in developed and developing countries.

**April.** TAG hosts activists from around the country to discuss the new **CCR5 inhibitor** class of anti-HIV drugs with scientist John Moore and Pfizer's Howie Mayer. TAG holds meetings on CCR5 inhibitors with the **AIDS Treatment Activists Coalition** (ATAC) and **Schering-Plough**. TAG and OSI host a **TB/HIV Advisory Committee** meeting in London to review TB/HIV advocacy grants and meet with UK policymakers, activists, and researchers.

**May.** TAG's Rob Camp testifies at the FDA approval hearing for a new protease inhibitor, **tipranavir** (**Aptivus™** from **Boehringer-Ingelheim**). On balance, because the drug seems useful for heavily pre-treated individuals, in spite of considerable toxicity, TAG recommends approval, as does the FDA advisory committee. TAG Board member Rich Lynn hosts a reception for TAG donors and community.

**June.** FDA approves **tipranavir**, and **Boehringer-Ingelheim** (BI) prices it at an outrageous **\$13,410** per year. Activists issue protest but BI disregards them. Javid Syed coordinates the first global community activist nominations to the **Stop TB Partnership**. Mark Harrington is the community representative to the **writing committee revising guidelines for antiretroviral therapy in resource-limited settings** for the **World Health Organization** (WHO). Mark also initiates a far-reaching activist campaign to improve the draft **Global Plan to Stop TB 2**, incorporating more ambitious targets for TB/HIV control.

**July.** TAG leads a coalition pressuring Congress to preserve the powers of the **NIH Office of AIDS Research** (OAR). TAG's Javid Syed leads activist workshops on TB/HIV at the **International Conference on AIDS in Asia and the Pacific** (ICAAP) in **Kobe, Japan**, and at the **Pan-African Treatment Access Movement** (PATAM) treatment literacy

## R E S E A R C H I N A C T I O N A W A R D S



**Left:** RIAA Recipient **NY State Senator Tom Duane** with Presenter **U.S. Senator Chuck Schumer** (D-NY)

**Center:** RIAA Recipient **Dr. Bruce Schackman** with TAG Board President **Barbara Hughes**

**Right:** TAG Board Members **Mark O'Donnell** and **Jason Osher**, Executive Director **Mark Harrington**, Board Member **Lynda Dee**, RIAA Recipient **John Waters**, and Board Members **Joy Episalla** and **Monte Steinman**

workshop in **Douala, Cameroon**, and is quoted in *The New York Times* advocating for greater investment in TB research. TAG publishes and distributes over 1,000 copies of *What's in the Pipeline* at the **International AIDS Society Conference on Pathogenesis & Treatment** in Rio de Janeiro, Brazil. The report is well received and staff regularly update their pipelines online over the year.

**August.** **Mark Harrington's** article on "Ten Years of HAART" appears in Houston's *RITA!* newsletter ([www.centerforaids.org/rita/0805/overview.pdf](http://www.centerforaids.org/rita/0805/overview.pdf)).

**September.** **Tracy Swan** completes a report for the **Health Resources & Services Administration (HRSA)** to educate AIDS providers about integrating care for **hepatitis C virus (HCV)** into AIDS care programs. **Rob Camp** is elected co-chair of the **Drug Development Committee (DDC)** of the **AIDS Treatment Activists Coalition (ATAC)**, which meets with drug manufacturers to promote faster, more informative research studies, expanded access programs, and full post-marketing studies. *Science* magazine publishes an article on the Pre-exposure Prophylaxis (PrEP) trials controversy and the way forward, co-authored by **Mark Harrington**.

**October.** TAG leads a global coalition of activists who call for "**A Revolution in Tuberculosis (TB) Prevention, Care and Treatment**" at the **36th World Congress on Lung Health**. After global mobilization, activists win a significant victory by successfully demanding that *The Global Plan to Stop TB: 2006-2015* include much more rapid scale-up of interventions for TB/HIV. TAG coordinates the **4th International TB/HIV Community Workshop** in Paris, attended by 70 activists worldwide. **Tracy Swan** attends the **American Association for the Study of Liver Disease (AASLD)** conference in San Francisco where she meets with

several companies developing experimental HCV compounds, including **Valeant** (maker of **viramidine**, a **ribavirin** prodrug), **Intermune** (makers of **consensus interferon**), and **XTL** (makers of an **HCV monoclonal antibody**), with HCV researchers, and with the FDA, to speed up new HCV drug development and to spur new thinking.

**November.** **Rob Camp** and **Javid Syed** attend the **North American AIDS Treatment Action Forum** in **Oaxaca, Mexico**, where Javid leads a workshop on TB/HIV coinfection. **Mark Harrington** travels to TB research sites in **South Africa** and **Zambia** on a Gates Foundation site visit as a community observer to the **CREATE consortium's trials to prevent HIV-related TB**. Congress passes a disgracefully inadequate 0.5% increase for **NIH**, but fails to move on **NIH reauthorization**, thus preserving OAR's authority for the time being.

**December.** TAG is awarded a four-year **Basic Science, Vaccines, and Prevention Project** grant from the **Michael Palm Foundation**. On December 11th, TAG holds the **Research in Action Awards** at Artists Space, honoring **State Senator Tom Duane**, AIDS researcher **Dr. Bruce R. Schackman**, and director **John Waters**. **Tracy Swan** helps to persuade **Senator Hillary R. Clinton (D-NY)** to cosponsor the **Hepatitis C Epidemic Prevention and Control Act**. **Javid Syed** and **Mark Harrington** attend the Global Alliance for TB Drug Development's open forum on regulatory issues in TB drug development in Crystal City, Virginia, where Mark gives the keynote address on "**Lessons from AIDS Research for TB**." Javid and Mark meet with the **Office of the Global AIDS Coordinator** to encourage them to strengthen PEPFAR's TB/HIV work. **Richard Jefferys' "2005 - Basic Science, Vaccines, and Immunology Overview,"** is published online at [www.aidsinfonyc.org/tag/science/2005YearInReview.html](http://www.aidsinfonyc.org/tag/science/2005YearInReview.html)

R E S E A R C H I N A C T I O N A W A R D S



**Left:** TAG Board Treasurer **Laura Morrison**, Executive Director **Mark Harrington**, Board President **Barbara Hughes**, and RIAA Recipient **State Senator Tom Duane**  
**Center:** **Jackie Hoffman**, Mistress of Ceremonies  
**Right:** Presenter **Kathleen Turner** and RIAA Recipient **John Waters**

## TAG PROGRAMS

**Antiretroviral Project.** TAG closely monitors HIV anti-retroviral drugs in all stages of development, including post-marketing. We advocate for the expeditious development, proper clinical research and regulation, ease of access and optimal use of these drugs. We work with other treatment activists and researchers, FDA, NIH, and the pharmaceutical industry to achieve these objectives. TAG also helps educate members of the HIV community about antiretrovirals.

**Michael Palm HIV Basic Science, Vaccines, & Prevention Project.** TAG's work on basic science advocacy is devoted to speeding the conduct of research on the pathogenesis of HIV infection (how HIV causes disease) and the interactions between the virus and the immune system. We believe that a greater understanding in these areas will pave the way for better treatments for HIV infection and an eventual vaccine to protect against HIV transmission. TAG accomplishes its advocacy work by providing analyses of the scientific and practical impediments that slow the progress of basic research, offering recommendations to expedite progress and pushing for the adoption of these measures. TAG also works to speed our progress towards the development of a vaccine against HIV transmission and immune based therapies for people with HIV. We work with industry and government sponsors of research in this area to push for more and better research, offering recommendations for change based on analyses of ongoing efforts.

**Hepatitis C Virus (HCV) Coinfection Project.** TAG closely monitors new data on the epidemiology and natural history of hepatitis C and HIV/HCV coinfection, as well as the development of new diagnostics, prophylaxis, and treatments for hepatitis C in pre- and post-marketing stages. We advocate for expeditious development, proper clinical research and regulation, and optimal use of these drugs. We oversee HIV drug development, and advocate for research of antiretroviral agents and treatment strategies

for people coinfecting with viral hepatitis. We develop and promote policies to increase access to hepatitis C care and treatment, especially for high-prevalence populations. We work with the pharmaceutical companies, NIH, FDA, and other government agencies as well as researchers and other treatment activists to achieve these objectives. TAG also educates members of the HIV community about coinfection with hepatitis C.

**TB/HIV Project.** The TB/HIV Project works to combat TB/HIV coinfection through a combination of community-based advocacy, education, and mobilization efforts involving AIDS advocates in developed and developing countries. The TB/HIV Project is currently supported by a two-year grant from the Bill & Melinda Gates Foundation.

**Federal Affairs / NIH Project.** TAG advocates for responsible public policy on AIDS research and treatment with our nation's leaders, including members of Congress and officials from agencies in the Executive Branch. We push for more funding for AIDS research and sensible legislative initiatives to foster better biomedical research. TAG also advocates for sound regulatory policy in the evaluation of AIDS drugs which balances the need for access to new agents and the need for reliable information about their clinical safety and efficacy.

**Community Education, Mobilization, Publications & Website.** TAG educates communities affected by HIV in the U.S. and globally about the latest developments in research and treatment, and trains and mentors individuals to advocate on their behalf. These activities include playing a leadership role in the North American AIDS Treatment Action Forum (NATAF) and helping to organize trainings for the AIDS Treatment Activists Coalition (ATAC) and its Drug Development Committee (DDC). TAG publishes periodic updates on research, treatment, and policy, including *TAGline*, *TAG Update*, and the TAG websites, [www.treatmentactiongroup.org](http://www.treatmentactiongroup.org) and [www.aidsinfonyc.org/tag](http://www.aidsinfonyc.org/tag).

## R E S E A R C H I N A C T I O N A W A R D S



**Left:** TAG Executive Director **Mark Harrington**, Board Member **Lynda Dee**, and RIAA Recipient **John Waters**  
**Right:** TAG Board Member **Alby Maccarone**, Mistress of Ceremonies **Jackie Hoffman**, Executive Director **Mark Harrington**, Actress and RIAA Presenter **Kathleen Turner**, RIAA Recipient **John Waters**, and Board Member **Joy Episalla**



**TREATMENT ACTION GROUP, INC.  
STATEMENTS OF FINANCIAL POSITION**

**A S S E T S**

<b>Current assets:</b>	<b>Years ended December 31,</b>	
	<b>2 0 0 5</b>	<b>2 0 0 4</b>
Cash and cash equivalents	\$ 622,109	\$ 403,725
Contributions receivable	70,625	613,429
Prepaid expenses and other receivables	2,859	1,506
<b>Total current assets</b>	<b>695,593</b>	<b>1,018,660</b>
Property and equipment - net of accumulated depreciation	8,606	12,333
Security deposits	4,455	4,455
<b>Total assets</b>	<b><u>\$ 708,654</u></b>	<b><u>\$ 1,035,448</u></b>

**LIABILITIES AND NET ASSETS**

Current liabilities		
Accounts payable and accrued expenses	\$ 5,352	\$ 12,664
<b>Total liabilities</b>	<b><u>5,352</u></b>	<b><u>12,664</u></b>
Net assets		
Unrestricted	272,262	250,717
Temporarily restricted	431,040	772,067
<b>Total net assets</b>	<b><u>703,302</u></b>	<b><u>1,022,784</u></b>
<b>Total liabilities and net assets</b>	<b><u>\$ 708,654</u></b>	<b><u>\$ 1,035,448</u></b>

[TAG's 2004 year-end temporarily restricted assets includes the second payment of support from the Bill & Melinda Gates Foundation for the TB/HIV Project. The funding was committed in 2004 but received in 2005.]

**STATEMENTS OF CASH FLOWS**

<b>Cash flows from operating activities:</b>		
(Decrease) Increase in net assets	\$ (319,482)	\$ 689,563
Adjustments to reconcile increase in net assets to net cash provided by operating activities:		
Realized loss on sale of marketable securities	-	466
Depreciation	4,867	5,939
(Increase) Decrease in current assets:		
Due from vendor	-	3,937
Prepaid expenses and other receivables	(1,353)	(582)
Contributions receivable	542,804	(566,314)
Security deposits	-	(1,699)
(Decrease) Increase in current liabilities:		
Accounts payable and accrued expenses	(7,312)	3,974
<b>Net cash provided by operating activities</b>	<b><u>\$ 219,524</u></b>	<b><u>\$ 135,284</u></b>
<b>Cash flows from investing activities:</b>		
Proceeds from sale of marketable securities	-	7,366
Purchases of property and equipment	(1,140)	-
Net cash (used in) provided by investing activities	<u>(1,140)</u>	<u>7,366</u>
<b>Net increase in cash balance</b>	<b>218,384</b>	<b>142,650</b>
<b>Cash, beginning of year</b>	<b><u>403,725</u></b>	<b><u>261,075</u></b>
<b>Cash, end of year</b>	<b><u>\$ 622,109</u></b>	<b><u>\$ 403,725</u></b>

**TREATMENT ACTION GROUP, INC.  
STATEMENTS OF ACTIVITIES**

	Unrestricted	Temporarily Restricted	Years ended December 31	
			2 0 0 5	2 0 0 4
<b>Revenue and support:</b>				
Direct mail	\$ 48,697	\$ -	\$ 48,697	\$ 36,034
Donations	26,626	-	26,626	13,850
Grants	291,950	15,000	306,950	1,365,189
Special event income	110,552	-	110,552	70,853
Travel and other reimbursement	16,826	-	16,826	3,733
Interest and dividend income	2,069	4,947	7,016	3,404
	<u>496,720</u>	<u>19,947</u>	<u>516,667</u>	<u>1,493,063</u>
Net assets released from restrictions	<u>360,974</u>	<u>(360,974)</u>	<u>-</u>	<u>-</u>
<b>Total revenue and support</b>	<b>857,694</b>	<b>(341,027)</b>	<b>516,667</b>	<b>1,493,063</b>
<b>Expenses</b>				
<b>Program services</b>				
Antiretroviral project	101,380	-	101,380	101,046
Federal Affairs/NIH project	6,388	-	6,388	11,822
Basic Science and Vaccines project	101,451	-	101,451	96,060
HCV Coinfection project	93,719	-	93,719	95,113
TB/HIV Project	360,974	-	360,974	246,841
Community outreach program	6,044	-	6,044	10,228
TAGline/Website	32,904	-	32,904	73,568
International program	10,296	-	10,296	13,895
<b>Total Program expenses</b>	<b>713,156</b>	<b>-</b>	<b>713,156</b>	<b>648,573</b>
<b>Supporting services expenses</b>				
Management and general	68,652	-	68,652	89,430
Fundraising	54,341	-	54,341	65,497
<b>Total services expenses</b>	<b>836,149</b>	<b>-</b>	<b>836,149</b>	<b>803,500</b>
<b>Increase (Decrease) in net assets</b>	<b>21,545</b>	<b>(341,027)</b>	<b>(319,482)</b>	<b>689,563</b>
<b>Net assets, beginning of year</b>	<b>250,717</b>	<b>772,067</b>	<b>1,022,784</b>	<b>333,221</b>
<b>Net assets, end of year</b>	<b>\$ 272,262</b>	<b>\$ 431,040</b>	<b>\$ 703,302</b>	<b>\$ 1,022,784</b>



**\$ 100,000 or more**

The Bill & Melinda Gates Foundation

**\$ 50,000 - \$ 99,000**

Paul L. Newman

**\$ 25,000 - \$ 49,999**

Bristol-Myers Squibb Company  
The Irene Diamond Fund  
GlaxoSmithKline  
Hoffmann-LaRoche, Inc.

**\$ 10,000 - \$ 24,999**

Boehringer Ingelheim Pharmaceuticals Inc.  
Broadway Cares / Equity Fights AIDS  
Gesso Foundation  
Gilead Sciences  
John M. Lloyd Foundation  
JPMorgan Private Bank  
Merck & Co.  
The Rainbow Endowment  
Terry K. Watanabe Charitable Trust

**\$ 5,000 - \$ 9,999**

David Corkery  
Marcus Edward  
Richard M. Lynn & Joseph Evall  
Robert J. McLain  
Mark O'Donnell  
Open Society Institute  
The Mary Wohlford Foundation

**\$ 2,500 - \$ 4,999**

Tim Casey & Mary C. Rieth Casey  
Nicholas A.R. Debs  
Richard A. & Barbara Knowles Debs  
M. Lee Garrison  
Karl J. Jepsen & James M. Goldrick  
Alby P. Maccarone, Jr.  
Stephen Mack & Robert E. Monteleone  
J. Michael McCune, MD, &  
Karen Kaye Smith-McCune

**\$ 1,000 - \$ 2,499**

Katherine C. & Thomas M. Ash  
Michael A. Becker & Tee Scatuorchio  
Concerned Parents for AIDS Research  
Courtroom Television Networks  
Constance D'Aurizio  
Edward J. Davis & Thomas D. Phillips  
Paul A. Dierkes  
Paul L. Dietz  
Randall G. Drain  
William French & Gayle Funk French,  
*In memory of Jay Kevin Funk*  
Guido Goldman  
Richard & Judith Harrington  
David Hollander & Robert Shaw  
Lawrence H. Hoskins  
Mathilde Krim, PhD  
Carey C. Maloney & Hermes Mallea

Mobley & Company,  
The Family of Lawrence H. Cave III, PhD  
Jason I. Osher & Richard R. Schubel  
Mario Roirelli  
Bruce R. Schackman, PhD, &  
Edward K. Sikov  
Nina Schwalbe Fund of Tides Foundation  
Evan Schwartz & Robert Fitterman  
Monte Steinman  
W. Kirk Wallace & Mark M. Sexton,  
Wallace-Sexton Fund of Stonewall  
Community Foundation  
The Zacks Family Foundation

**\$ 500 - \$ 999**

The AIDS Institute  
Christine, Benjamin & Darius Anagnos  
Jeffrey Arnstein & Michael Field  
Leonard S. Barton  
Cary Brown & S. Chris Shirley  
Drs. Mark A. & Lisa Rowland Callahan  
Eli Camhi  
Paula Chalfin  
Gene Copello, PhD  
Michael Cowing  
Stephanie Cowles  
Alice Cray & Nathaniel Hupert  
Lynda M. Dee, Esq.  
Peter F. Diffly  
Pierre G. Durand  
Joy Episalla & Carrie Yamaoka  
Steven M. Frank & Elizabeth Powell, MD  
Perry N. Halkitis, PhD, & Leslie L. Smith  
Bryan A. Hilbert  
James C. Hormel  
Donald Johannessen, MD  
Lee R. Jones  
Paul E. Kennedy  
Noel E.D. Kirnon & Michael D. Paley  
Anna D. Kramarsky &  
Jeanne L. Bergman, PhD  
Christian D. Kraus & Jamie Bishton  
Michael K. Longacre  
Loring R. McAlpin  
Kenneth T. Monteiro & Leo J. Blackman  
Laura A. Morrison  
Walter M. & Dulcie Schackman  
Marvin Shulman  
John A. Silberman & Elliot Carlen  
Jane Silver  
Mort & Margaret Steinberg  
Jan A. Wysocki  
William J. Zwart & David W. Berchenbriter

**\$ 250 - \$ 499**

Mary S.R. & Troy Alexander  
Peter Lewis Allen  
Paul Beirne  
Suzanne S. & Bernard Benzer  
Meredith C. & Frank V. Bove  
Lynne Brown

Richard M. Buxbaum &  
Catherine B. Hartshorn  
Dr. & Mrs. Charles C.J. Carpenter  
Jeanie Carstensen  
Scott B. Cook  
BC Craig & Ruth Finkelstein  
Denise B. & Thomas H. Dailey, MD  
M. Shane Dawson, MD  
Joseph DiNorcia &  
Mary Ann Sheehan-DiNorcia  
Carol H. & John L. Field  
Hartly Fleischmann  
Joseph T. Flynn, MD  
Kenneth S. Fornataro  
Ronald J. Goldberg & Joe Chiplock  
Barry Goralnick Architects  
Christopher Harrington & Daphne Powell  
Mark Harrington  
Walter L. & Dianne M. Harrison  
Lawrence R. Horne  
Philip M. Kayal  
Maura Keaney & Mark Guma  
Edward J. Kennedy  
Richard M. Kielar &  
Christian Zimmermann  
Charles Kreloff & David Saylor  
Jeffrey M. Matusow  
F. Joseph McConnell & Erik Haagensen  
George J. & Mirla Morrison  
Alvin I. & Linda L. Mushlin  
April Newbauer & Nicholas Poser  
Ana Oliveira / Gay Men's Health Crisis  
Michael J. Park & James F. Quinn  
Donna M. Pauldine  
Judith D. & Samuel P. Peabody  
Eddie Pelto  
Patricia & John Pollok  
Kenneth F. Rash & Scott L. Ofstead  
Richard L. & Nancy Rubens  
Lorraine Sahagian  
Peter A. Schamel  
Steven M. Scott  
James C. & Susan Shehan  
John F. Shekleton  
Betty C. Sikov  
Derick A. Smith  
Joseph W. Smith  
Jonathan Starch  
John M. Stephenson & Luke Vahle  
Paul A. Teixeira  
Keith S. Tobin, MD  
Mary B. Tokar  
Joel Wachs  
Frederick Wertheim  
David E. Winckoski  
W. Douglas Wingo & Tim Legg  
Mark B. Wyn  
Peter J. Zuur

**Thank You!**

## **Michael Palm Foundation Awards TAG \$1 Million to Expand HIV Pathogenesis & Prevention Research Project to Strengthen HIV Immunology, Vaccine, and Prevention Research Advocacy**

On December 1, 2005 – World AIDS Day – TAG announced the establishment of the Michael Palm HIV Pathogenesis and Prevention Research Project. The Project will work to strengthen basic science, immunology, and biomedical HIV prevention research efforts directed at clarifying understanding of how HIV destroys the immune system, how to develop effective immune-based therapy strategies, and how to develop biomedical preventive approaches such as vaccines, microbicides, and treatments to prevent HIV infection pre- and post-exposure. The Michael Palm HIV Pathogenesis and Prevention Research Project is supported by a four-year, \$1 million grant from the Michael Palm Foundation. TAG will use this grant to intensify its advocacy efforts on improving HIV pathogenesis and immunology research, and to accelerate the development of safe and effective immune-based therapies, vaccines, microbicides, and other tools to treat, prevent, and cure HIV infection. TAG named the Project to honor Michael Palm's legacy of generous support for TAG's cutting-edge work.

### **TAG MISSION STATEMENT**

The Treatment Action Group (TAG) fights to find a cure for AIDS and to ensure that all people living with HIV receive the necessary treatment, care, and information they need to save their lives. TAG focuses on the AIDS research effort, both public and private, the drug development process, and health care delivery systems. We meet with researchers, pharmaceutical companies, and government officials to encourage exploration of understudied areas in AIDS research and speed up drug development, approval, and access. We work with the World Health Organization and community organizations globally, and strive to develop the scientific and political expertise needed to transform policy. TAG is committed to working for and with all communities affected by HIV.

TAG is a non-profit corporation with 501c (3) status. Contributions are tax deductible to the extent allowed by law.



#### **TREATMENT ACTION GROUP**

611 Broadway, Suite 608  
New York, New York 10012 USA  
212.253.7922 tel. / 212.253.7923 fax  
[www.treatmentactiongroup.org](http://www.treatmentactiongroup.org)

### **BOARD OF DIRECTORS**

Barbara Hughes  
*President*

Laura Morrison  
*Secretary / Treasurer*

M. Shane Dawson, M.D.

Lynda Dee, Esq.

Joy Episalla

Richard Lynn, Ph.D.

Alby P. Maccarone, Jr.

Mark O'Donnell

Jason Osher

Monte Steinman

### **STAFF**

Mark Harrington  
*Executive Director*

Rob Camp  
*Antiretroviral Project Director*

Richard Jefferys  
*Michael Palm Basic Science, Vaccines &  
Prevention Project Director*

Tracy Swan  
*Hepatitis C Coinfection Project Director*

Javid Syed  
*TB/HIV Project Director*

Joseph McConnell  
*Administrator*